2014 Prix Galien Award for Best Medical Technology goes to Stryker for Neuro Clot Remover

Stryker’s clever neuro blood-clot removal device has received the Prix Galien USA 2014 Award for Best Medical Technology.

Background

We’ve followed the progress of Stryker Corporation’s Trevo® ProVue Retriever for a while now, so it’s only appropriate that we cover the news that it has been awarded a prestigious medical device award.

35-40% of the estimated 795,000 strokes every year that happen in the United States are considered “large vessel” ischemic strokes, resulting from a blood clot in one of the major arteries in the brain. If left untreated, patient prognosis with this type of stroke is very poor, with mortality rates as high as 86%. The frontline medical therapy for ischemic stroke is a clot-busting drug (IV tPA) that is administered intravenously. Studies have shown that IV tPA has only a 6-44% success rate in dissolving the clot in an intracranial large vessel occlusion.

For patients ineligible to receive IV tPA, or where IV tPA has been unsuccessful, the Trevo ProVue Retriever offers a minimally-invasive surgical option for removing the clot. The Trevo device is designed to restore blood flow in the neurovasculature by removing blood clot in patients experiencing ischemic stroke. It is the first and only so-called Stentriever® Device fully visible under fluoroscopic imaging, and claims to set a new standard in precision placement, visualization of the device/clot interaction and clot retrieval.

The landmark TREVO 2 Trial, a prospective, randomized trial, has shown revascularization rates of up to 92%. High revascularization rates and ease of use have resulted in rapid adoption of the Trevo ProVue Retriever. With an expanded physician use base, hospitals around the world are now increasingly able to offer this proven medical treatment for ischemic stroke.

Created in 1970 and named after Galen, the father of medical science and modern pharmacology, the Prix Galien’s ongoing mission is to recognize the technical, scientific and clinical research skills necessary to develop innovative medicines. 

Company comments

“We are thrilled to be recognized by the Galien Foundation and honored to be among such a prestigious group of recipients of this year’s award,” said Mark Paul, President, Global Neurovascular, Stryker. “We strive to introduce innovative medical technologies that can help improve patient outcomes. The Trevo ProVue Retriever represents a truly innovative medical product and one that has brought about a new era in ischemic stroke management and intracranial clot retrieval.”

Source: Stryker Corporation, PR Newswire

Share your thoughts

Your email address will not be published. Required fields are marked *